Results 71 to 80 of about 4,368 (233)

Headache characteristics in acromegaly: Only a secondary disorder?

Headache: The Journal of Head and Face Pain, Volume 65, Issue 5, Page 826-834, May 2025.
Abstract Objective To investigate the characteristics and nature of headache in a population of patients with acromegaly. Background Headache is frequently described by patients with pituitary adenomas. Although it is mainly considered a secondary disorder, it can persist despite effective therapy for pituitary disease. A proper description of headache
Giada Giuliani, Denise Costa, Chiara Pellicano, Patrizia Gargiulo, Camilla Virili, Vittorio Di Piero, Marta Altieri   +6 more
wiley   +1 more source

Real-world comorbidities and treatment patterns of patients with acromegaly in two large US health plan databases [PDF]

, 2012
Acromegaly is a rare, chronic, and debilitating disease that results from excessive growth hormone production. Clinically, this disease is associated with enlargement of soft tissue, excessive skeletal growth, and increased risk of cardiovascular disease.
Elisabeth Le Nestour, Maureen Neary, Tanya Burton, Tim Bancroft   +3 more
core   +1 more source

Pegvisomant and Pasireotide LAR as second line therapy in acromegaly: Clinical effectiveness and predictors of response.

European Journal of Endocrinology, 2020
BACKGROUND The treatment of acromegaly resistant to first generation somatostatin receptor ligands (SRLs) is often difficult. Pegvisomant and Pasireotide LAR are mostly used in these subset of patients, as second line therapies.
S. Chiloiro, A. Giampietro, F. Mirra, F. Donfrancesco, T. Tartaglione, P. Mattogno, F. Angelini, L. Lauretti, M. Gessi, C. Anile, G. Rindi, A. Giustina, M. Fleseriu, A. Pontecorvi, L. De Marinis, A. Bianchi   +15 more
semanticscholar   +1 more source

Identification of Coagulation and Fibrinolysis‐Associated Biomarkers With Implications for Preeclampsia

Genetics Research , Volume 2025, Issue 1, 2025.
Background: Coagulation system abnormalities contribute to clinical manifestations in preeclampsia (PE), but the mechanisms of coagulation and fibrinolysis in PE are unclear. Methods: We utilized the Gene Expression Omnibus (GEO) database to obtain the GSE10588 training set and GSE54618 validation set.
Yujie Liu, Tingting Chen, Cuifang Fan, Irfan Ahmad   +3 more
wiley   +1 more source

Diabetes mellitus in acromegaly: prevalence, pathophysiological particulars and treatment strategies

Alʹmanah Kliničeskoj Mediciny, 2023
The prevalence of diabetes mellitus in acromegaly is significantly higher than that in the general population. Carbohydrate metabolism abnormalities often precede other phenotypic manifestations of acromegaly.
Irena A. Ilovayskaya, Gagik R. Galstyan
doaj   +1 more source

A consensus on the diagnosis and treatment of acromegaly complications [PDF]

, 2014
In March 2011, the Acromegaly Consensus Group met to revise and update the guidelines on the diagnosis and treatment of acromegaly complications. The meeting was sponsored by the Pituitary Society and the European Neuroendocrinology Association and ...
Bronstein, M. D., Casanueva, F. F., Chanson, P., Giustina, A., Klibanski, A., Lamberts, S. W., Melmed, S., Strasburger, C. J., Wass, J. A. H.   +8 more
core   +1 more source

Multidisciplinary Management of Pituitary Neuroendocrine Tumors During Pregnancy: Institutional Report

International Journal of Endocrinology, Volume 2025, Issue 1, 2025.
Background: Management of pituitary neuroendocrine tumors (pitNETs) during pregnancy is challenging. Involvement of the multidisciplinary team (MDT) may benefit the collaborative decision‐making. However, this aspect has not been well documented. We provided cases with pitNETs during pregnancy and summarized our experience on the MDT‐guided management.
Zhiyuan Xiao, Xiaopeng Guo, Yong Yao, Jifang Liu, Wei Lian, Kan Deng, Yu Zhang, Xia Zhang, Yuanli Zhao, Yi Zhang, Bing Xing, Huijuan Zhu, Suraiya Saleem   +12 more
wiley   +1 more source

Validation of serum IGF-I as a biomarker to monitor the bioactivity of exogenous growth hormone agonists and antagonists in rabbits [PDF]

, 2014
The development of new growth hormone (GH) agonists and growth hormone antagonists (GHAs) requires animal models for pre-clinical testing. Ideally, the effects of treatment are monitored using the same pharmacodynamic marker that is later used in ...
Bannink, Berger, Bidlingmaier, Bielohuby, Bielohuby, Bielohuby, Blum, Clemmons, Clemmons, Costa, Courtland, Cox, Daniel-Carlier, Divisova, Domené, D’Ercole, Festoff, Flisikowska, Friedrich, Friedrich, Fu, Grönbladh, Grønbaek, Hossenlopp, Kargi, Kassem, Katter, Katz, Katznelson, Keller, Key, Kopchick, Kopchick, Laeger, Le Roith, Masyuk, Metzger, Møller, Nason, NCCLS, Petersenn, Pinkert, Péter, Rosskopf, Schiller, Sievers, Thakur, Turner, van der Lely, Veldhuis, Veldhuis, Wallis, Wolf, Zapf, Zhang   +54 more
core   +3 more sources

Transformative Impact of Nanocarrier‐Mediated Drug Delivery: Overcoming Biological Barriers and Expanding Therapeutic Horizons

Small Science, Volume 4, Issue 11, November 2024.
The development of drug delivery systems is revolutionizing therapeutic progress by ensuring precise targeting and optimal drug concentrations. Nanocarriers, with their customizable properties and controlled release, overcome biological barriers to improve treatment outcomes. This study explores the potential of integrating artificial intelligence with
Minhye Kim, Myeongyeon Shin, Yaping Zhao, Mrinmoy Ghosh, Young‐Ok Son   +4 more
wiley   +1 more source

Burden of diabetes mellitus in patients with acromegaly treated with second-line pharmacotherapy in Spain

ClinicoEconomics and Outcomes Research, 2019
Laura Sánchez-Cenizo,1 Javier Aller,2 José Manuel Martínez-Sesmero,3 Nuria Mir,1 Carmen Peral,1 Darío Rubio-Rodríguez,4 Carlos Rubio-Terrés41Medical Department, Pfizer, S.L.U, Madrid, Spain; 2Endocronology ...
Sánchez-Cenizo L, Aller J, Martínez-Sesmero JM, Mir N, Peral C, Rubio-Rodríguez D, Rubio-Terrés C   +6 more
doaj